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ABSTRACT
Purpose: To evaluate the pattern of care in patients with high risk non muscle invasive bladder cancer (NMIBC) 
in the Comprehensive Cancer Center North-Netherlands (CCCN) and to assess factors associated with the 
choice of treatment, recurrence and progression free survival rates.
Materials and Methods: Retrospective analysis of 412 patients with newly diagnosed high risk NMIBC. Clini-
cal, demographic and follow-up data were obtained from the CCCN Cancer Registry and a detailed medical 
record review. Uni and multivariate analysis was performed to identify factors related to choice of treatment 
and 5 year recurrence and progression free survival.
Results: 74/412 (18%) patients with high risk NMIBC underwent a transurethral resection (TUR) as single 
treatment. Adjuvant treatment after TUR was performed in 90.7% of the patients treated in teaching hospitals 
versus 71.8 % in non-teaching hospitals (p < 0.001). In multivariate analysis, age (60-79 years OR 0.40 and > 
80 years OR 0.1 p = 0.001) and treatment in non-teaching hospitals (OR 0.25; p < 0.001) were associated with 
less adjuvant treatment after TUR. Tumor recurrence occurred in 191/392 (49%) and progression in 84 /392 
(21.4%) patients. The mean 5-years progression free survival was 71.6% (95% CI 65.5-76.8).
Conclusion: In this pattern of care study in high risk NMIBC, 18% of the patients were treated with TUR as 
single treatment. Age and treatment in non-teaching hospitals were associated with less adjuvant treatment after 
TUR. None of the variables sex, age, comorbidity, hospital type, stage and year of treatment was associated 
with 5 year recurrence or progression rates.
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INTRODUCTION
 Bladder cancer is the second most common 
urological cancer. Non muscle invasive forms include 
carcinoma in situ (CIS) and Ta/T1 carcinomas and 
accounts for more than half of the incidence. These 
tumors frequently recur, particularly in multi focal 
disease. Progression to muscle invasive disease is 
 Clinical Urolog� 
doi: 10.1590/S1677-55382011000200007 
related to risk groups. The high risk group consists of 
patients with a high grade tumor (Grade 3) with/with-
out concurrent CIS or CIS alone. Progression rates in 
this group of patients show a wide range (12 - 52%) 
(1-3).
 Adjuvant intravesical chemotherapy, either 
single immediate or serial additional instillations, is 
effective in decreasing local recurrence in low grade 
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tumors (4,5). However, these instillations do not 
prevent progression. In high grade tumors Bacillus 
Calmette Guerin (BCG) instillations are superior to 
intravesical chemotherapy to prevent or delay progres-
sion. For optimal efficacy BCG maintenance therapy 
is necessary (1,3,6). If conservative treatment fails 
patients present with a recurrence of high risk bladder 
cancer with or without progression, the most common 
therapy is radical cystectomy. The exact timing of this 
cystectomy is still unclear and the subject of many 
studies.
 Despite the presence of guidelines towards 
management of bladder cancer of the American and 
European Urological Associations, the actual manage-
ment shows quite large variation. A great majority of 
surveyed urologists in the USA in 2003 were still re-
luctant to perform a cystectomy in patients with a high 
grade tumor who failed intravesical immunotherapy 
although this was described in the guidelines and a 
cystectomy in this group of patients gives a tumor-
specific survival of 80 - 90 % (7).
 In the Netherlands a national guideline for 
diagnosis and treatment of bladder cancer has been 
available since 2009. Until that moment regional 
consensus based guidelines are available within the 
regional comprehensive cancer centers. The current 
clinical practice roughly matches the European As-
sociation of Urology guidelines (8,9).
 Pattern of care studies are used to identify 
disparities in patient treatment. These studies can 
also evaluate which tumor related, patient related or 
other factors determine the treatment decisions and 
how this could influence the course and development 
of the treatment outcome (7,10,11).
 The aim of the study was to evaluate the actual 
pattern of care in patients with newly diagnosed high 
risk NMIBC and to assess factors associated with the 




 From the cancer registry of the CCCN a 
total of 535 patients were identified with a first 
manifestation of NMIBC in the period 1997-2002. 
We selected all cases with a non muscle invasive 
urothelial cell carcinoma stage Ta/1 G3 with/without 
CIS or isolated CIS of the bladder. Patients with 
metastatic disease (n = 5) and TxG3 (n = 8) were 
excluded. From 110 patients the medical records 
were not available for data collection on follow-up 
and recurrence. The data of these 110 patients in 
the CCCN registry showed identical characteristics 
and similar distribution regarding stage and grade of 
the tumor compared to the studied cohort. The final 
analytic cohort included 412 patients with high risk 
NMIBC of the bladder.
Data Collection by the Cancer Registries
 Data were collected by the regional cancer 
registry of the CCCN. Within the CCCN a total of 
15 hospitals participated including one University 
Medical Center and 3 major teaching hospitals. The 
nationwide Dutch network and registry of histo- 
and cytopathology regularly submits reports of all 
diagnosed malignancies to the cancer registries. 
Trained registry personnel collect data on demog-
raphy, diagnosis, staging, co-morbidity, treatment 
and follow-up from the medical records, includ-
ing pathology and surgery reports. Treatment was 
coded in sequence of administration to a maximum 
of four treatment modalities. Vital status was es-
tablished either directly from the patient’s medical 
record or through linkage of cancer registry data 
with the municipal population registries. Stage 
was based on pathological information of primary 
tumor or first recurrence. CIS is only registered as 
CIS in cases of isolated CIS; concomitant CIS is 
included in the group Ta/T1G3 tumor. BCG-fail-
ure was defined as recurrent disease in patients 
who were treated with a first course of 6 instilla-
tions of BCG. Teaching hospitals were defined as 
hospitals which provide training for residents to 
become urologist. We analyzed the retrospective 
data anonymously and therefore no formal Eth-
ics Committee approval was needed. The local 
oncology committees have granted permission to 
examine the medical files of the included patients 
for additional data which were collected.
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Statistics
 To assess the factors associated with choice 
of treatment we used a logistic regression analysis. 
Age was studied as a continuous factor and grouped 
using decades. Time to local recurrence is defined as 
the time from diagnosis to the registered histological 
proven recurrence in the bladder after prior treat-
ment. Progression time was defined as time from 
diagnosis to any registered recurrent tumor with 
progression in T-stage, arising concomitant CIS or 
progression to lymph node or distant metastases. Dif-
ferences in 5 year Recurrence-Free Survival (RFS) 
and Progression-Free Survival (PFS) were assessed 
using the log-rank test. The effect of several factors 
on 5 year RFS and PFS were studied using a multi-
variable Cox regression analysis. As cause of death 
was unknown in 19.8% of the patients we choose to 
use relative survival. The relative survival has been 
shown to be a good estimator of the disease specific 
survival in absence of information on the cause of 
death or in case information on the cause of death is 
inaccurate (12). The relative survival estimates the 
net bladder cancer survival, survival in the hypotheti-
cal situation that bladder cancer is the only possible 
cause of death. Maximum follow-up was curtailed at 
8 years. Relative excess risks of death were estimated 
using a multivariate generalized linear model with a 
Poisson error structure, based on collapsed relative 
survival data, using exact survival times (13).
RESULTS
Treatment
 Overall, 18% of the 412 patients with a high 
risk NMIBC underwent a TUR as single treatment 
(Table-1). Seventy-seven percent of the patients 
received adjuvant treatment with a single immediate 
Mitomycin (MMC)-instillation, MMC-instillations 
or BCG-instillations with or without a prior single 
MMC-instillation (3.3%, 39% and 34%, respectively). 
For the assessment of associating factors in the choice 
for TUR with adjuvant therapy 20 patients were ex-
cluded because of any other treatment (radiotherapy, 
cystectomy).
 As shown in Table-2, age was related to re-
ceiving adjuvant therapy (OR 0.94-95% CI 0.91-0.97) 
in univariate analysis. Patients younger than 60 years 
received adjuvant therapy in 92.2% of the cases and 
only 71.3% of the elderly patients (≥ 70 years) did 
receive adjuvant therapy. Patients treated in teaching 
hospitals received adjuvant treatment after the TUR 
























CIS   29   7.7
Treatment
TUR   76 18.4
TUR with single instillation 14 3.4
TUR with chemotherapy 160 38.8
TUR and BCG 142 34.5
Cystectomy   16   3.9
Radiotherapy    4   1.0
BCG = bacillus Calmette-Guérin; TUR = transurethral resection; 
CIS = carcinoma in situ.
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in 90.7% compared to 71.8% in patients treated in 
non-teaching hospitals (p < 0.001). In multivariate 
analysis, age (60-79 years OR 0.40 and > 80 years 
OR 0.1 p = 0.001) and treatment in non-teaching 
hospitals (OR 0.25; p < 0.001) were associated with 
less adjuvant treatment after TUR.
Progression-Free Survival
 Local recurrence was observed in 191 of the 
392 patients (48.2%) with their bladder in situ dur-
ing a mean follow up of 2,7 years (range 0.1 - 9.2). 
Of the 76 patients treated with TUR alone 44 (58%) 
showed recurrent disease versus 147 (49%) of the 
316 patients treated with adjuvant chemo or BCG 
therapy showed recurrent disease (hazard ratio (HR) 
0.66 (95% CI 0.47-0.93); p = 0.02). Median time to 
local recurrence was 2.6 years (range 0.10 - 9.20). 
None of the other variables sex, age, co morbidity, 
teaching/non-teaching hospitals, stage, year of treat-
ment was associated with local recurrence (data not 
shown).
 Tumor progression occurred in 84 of the 
392 patients (21.4%). The mean 5-years progres-
sion free survival was 71.6% (95% CI 65.5-76.8). 
In multivariate analysis disease progression showed 
a trend towards significance with stage (adjusted for 
age and type of growth) with a HR of 0.97(95% CI 
0.60-1.56) for T1G3/4 (as opposed to TaG3) and a HR 
of 0.13 (95% CI 0.02-0.97) for CIS with a p-value of 
0.1. None of the other registered factors was statisti-
cally significant associated with progression-free 
survival.
Table 2 – Transurethral resection.
Variable N TUR plus Adjuvant Univariate Analysis Multivariate Analysis
% p Value OR 95% CI p Value
Sex Male 339 80.2
Female 53 83.0 0.6
Age Continuous 392 80,6 <0.001
<60 64 92.2 Ref
60-69 117 83.8 0.4 0.1-1.2
70-79 145 82.1 0.4 0.1-1.1
>80 66 60.6 <0.001 0.1 0.04-0.4 < 0.001
Co-morbidity None 108 81.5
One 152 80.9
Two or more 132 79.6 0.9
Hospital Teaching 183 90.7 Ref
Non-teaching 209 71.8 <0.001 0.25 0.13-0.45 < 0.001
Stage TaG3 122 82.8
T1G3/4 241 78.4
CIS 29 89.7 0.3
Year  1997-1999 186 78.0
2000-2002 171 83.0 0.206
BCG = Bacillus Calmette-Guérin; TUR = transurethral resection; CIS = carcinoma in situ.
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Relative Survival
 During a median follow-up period of 4.5 
years (range 0.1 - 8.0), 164 of the 412 patients (39.8%) 
died. The 5-years relative survival was 81.9% (95% 
CI 75.2-88.0). Patients with one or more co-morbidi-
ties appeared to have a lower survival (5-years relative 
survival 70.8%) than patients with no co morbidity 
(95.2%; p = 0.084). None of the other registered fac-
tors was significantly associated with relative survival 
in either univariate or multivariate analysis.
BCG Failure
 Of the 142 patients initially treated with BCG 
76 patients (54%) failed after first course of BCG. 
Patients with CIS alone (42.9%) treated with BCG 
failed somewhat less often than patients with TaG3 
(52.9%) or T1G3 (55.8%) with or without CIS (p = 
0.4). BCG failure appeared to occur more often in 
patients with two or more co-morbidities (HR 1.38 p = 
0.2). Histology was not associated with BCG failure. 
Two thirds of the failures were still non muscle inva-
sive tumors (53/76). Nine of the patients were treated 
with a cystectomy (17%), while 26 were treated with 
a second course of BCG (34%).
COMMENTS
 In this pattern of care study for high risk 
NMIBC in the CCCN region more than 80% of 
patients were treated according to international stan-
dards. Only 18% of the patients were treated with a 
single TUR. We found hospital type and age to be 
associated with the choice for less adjuvant treatment. 
Both age and co morbidity appeared to influence 
progression-free and relative survival, but no other 
clinical factors were associated with progression, 
survival or BCG failure.
 In 1999 the AUA (American Urological As-
sociation) Bladder Cancer Guidelines Panel recom-
mended intravesical chemotherapy as a treatment 
option after endoscopic removal of low-grade Ta 
bladder cancer and intravesical BCG or MMC for CIS 
and after endoscopic removal of T1 and high grade Ta 
tumors (14). Later in 2004, Sylvester et al showed a 
lower rate of recurrence in patients who received in-
travesical therapy within 24 hours postoperatively.
 Worldwide the preference for TUR as single 
treatment for high risk NMIBC decreased throughout 
the last decade. In a pattern of care study by Snyder et 
al. 40% of the patients who were diagnosed in 1995 
with a high risk bladder tumor underwent resection 
only (11). In our cohort, a few years later, 18% did 
not receive adjuvant therapy.
 Remarkably in a pattern of care project of the 
2003 SEER program, data suggest still an underuse of 
intravesical therapy in patients with high risk NMIBC 
in the USA. Only 42 % of the 350 patients with high 
risk NMIBC received intravesical therapy. Stage, 
grade, race/ethnicity and geographic region were 
independently associated with intravesical therapy in 
this subcohort (10). Interestingly in this comparable 
study the use of adjuvant intravesical therapy was 
lower in academic hospitals (31%) as mentioned in 
the Editorial Comment on this study. In our study this 
was the opposite with adjuvant intravesical treatment 
in 90.7% of the patients treated in teaching hospitals 
versus 71.8% in non teaching hospitals.
 The proportion of patients receiving adjuvant 
therapy in our study is still low compared to opinions 
expressed by urologists in survey studies conducted in 
2003-2004. Witjes et al. (2006) observed that 94.6% 
of the Flemish and Dutch urologists would offer high 
risk patients at least an instillation course, predomi-
nantly BCG (15). In a survey in 2003 in the US 18% of 
the urologists stated to prefer TUR only for Ta-T1 high 
grade tumors and 8% and 1% for concurrent CIS and 
CIS only respectively (7). This difference in results 
between a survey study and a pattern of care study 
might be explained by self-selection of urologists 
that respond to questionnaires (around 50%) while 
the actual practice of all urologists was evaluated in 
a pattern of care study.
 We found 49 % (191/392) recurrences in the 
patients treated with adjuvant treatment after TUR. 
Progression rate 21.4% (84/392) is also similar to the 
figures presented in literature (1,3,6,16-20). Differ-
ences in the kind of adjuvant treatment did not appear 
to affect the progression rate. However, in our study 
it is not clear what percentage of patients treated with 
BCG in fact received long term maintenance therapy. 
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Bohle et al. demonstrated in a meta-analysis of com-
parative studies for BCG versus MMC a significant 
superiority for BCG for the prevention of tumor 
progression only if BCG maintenance therapy was 
provided (1). In a sub-analysis Sylvester et al. also 
showed superiority of BCG maintenance to MMC 
for patients with Tis (3). A clear overview of meta-
analyses of studies comparing intravesical therapies 
and differences was published by Hall et al. in 2007 
in an update of the guideline for the management of 
NMIBC (Stages Ta, T1 and Tis) (14). The individual 
patient data meta-analysis by Malmström in 2009 
showed again the superiority of BCG in the prevention 
of recurrences (21). Prior intravesical chemotherapy 
was not a confounder. Differences in outcome may be 
explained by heterogeneity of stage and grade of the 
included patients, different chemotherapeutical agents 
which are used and different durations of therapy.
 Because of concurrent CIS in the papillary 
tumor groups it is very difficult to draw any conclu-
sion about the separate effect of stage. Also there is 
limited inter- and intra-observer agreement in histo-
logical examination which affects the appropriateness 
of the staging. In a review pathology study the overall 
conformity in stage was only 50-60%, largely due to 
non-agreement for the low-stage tumors. Stage T1 
and CIS appear to be the most difficult entities to 
determine while the differentiation of these tumors 
is important in the decision regarding conservative 
or more aggressive therapy (22).
 The 5-year relative survival is 81% whereas 
almost 40% of the patients died during follow-up. 
Many patients probably died of other causes than 
their disease. It is obvious that multiple co-morbidi-
ties are associated with a worse relative survival. A 
retrospective study in 2002 on T1G3 tumor patients 
also did not find significant differences in survival 
between patients treated with BCG and transurethral 
resection alone (23).
 Many recent studies on T1G3 bladder tumor 
treated with BCG showed recurrences of 23 to 52% 
(1,6,16,17,19,20). The number of patients treated in 
those studies did not exceed 81, but the median fol-
low-up was longer than in our retrospective study. No 
difference was observed between groups of patients 
treated with or without the maintenance protocol after 
the induction therapy with BCG. Our study showed 
similar results with a recurrence rate of 54 % and a 
progression rate of 16% in 142 patients who were 
treated with BCG.
 Nowadays there is a tendency towards early 
cystectomy for recurrent T1 disease during or follow-
ing intravesical BCG therapy. This may be associated 
with better disease specific survival. Some investiga-
tors promote immediate cystectomy for T1G3 tumors 
(24). Differences in racial or ethnic background can 
also be an associating factor for tumor stage at the 
time of cystectomy (25). In our series 5.0% of the 
T1G3 tumors were treated with radical cystectomy 
after the diagnostic TUR. This is in concordance with 
the results of Joudi et al. which were 7% high risk 
patients who underwent radical cystectomy. Finally 
promising salvage therapies for patients with BCG 
failure, unsuitable for radical cystectomy, are awaited 
in the near future. Yates et al. recently published an 
update of the application of thermo-chemotherapy, 
intravesical interferon-alfa and electromotive drug 
administration (26).
 This study has limitations due to the retro-
spective design. We were not able to assess socio-eco-
nomic factors like educational level, income, social 
and martial status which are not recorded in the cancer 
registry and could not be obtained from the medical 
records. Any effects of race could not be assessed as 
the CCNN region consists of founder populations 
with > 95% of the inhabitants being Caucasians. Also 
specific determining factors in individual patients 
or in individual hospitals were not clarified. Finally 
any comparison of results between treatment groups 
like TUR versus TUR plus adjuvant treatment can be 
confounded by an indication bias.
CONCLUSION
 In this pattern of care study in high risk 
NMIBC, only 18% of the patients were treated with 
a single TUR. Age and treatment in non-teaching 
hospitals were associated with less adjuvant treatment 
after TUR. None of the variables sex, age, co morbid-
ity, teaching/non-teaching hospitals, stage and year of 
treatment was associated with 5 year local recurrence 
or with progression rates. Comorbidity was associated 
with a lower relative survival.
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EDITORIAL COMMENT
 The authors examined 412 patients (diag-
nosed between 1997-2002) within the North-Nether-
lands Cancer Registry for variation in the use of ad-
juvant therapy in patients with high risk superficial 
bladder cancer (defined as high grade Ta/T1 or CIS). 
82% of patients received some form of adjuvant in-
travesical therapy. Of patients receiving adjuvant 
therapy, 4% received only a single peri-operative 
installation, while induction BCG or chemotherapy 
was given in 45% and 51% of patients, respectively. 
It is unclear from the presented data what proportion 
of patients receiving induction therapy also received 
a peri-operative dose. Overall, these results suggest a 
much higher rate of compliance with published treat-
ment guidelines than that found in similar studies in 
the Unites States (ref. 10 and 11 in article). Surpris-
ingly, increasing age, but not co-morbidity, was sig-
nificantly associated with lower odds of intravesical 
therapy use. Contrary to the findings of Huang et al. 
(ref. 10), the use of adjuvant intravesical therapy was 
greater in teaching versus non-teaching hospitals in 
the Netherlands.
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2002 (ref. 8), it will be interesting going forward to 
re-examine these findings as further dissemination 
has hopefully occurred.  In addition, newer guide-
lines by the AUA (ref. 14) and EAU (2) emphasize 
re-resection of high grade T1 lesions (even with 
muscle in the initial specimen) as well as the use 
of maintenance therapy. It will also be important to 
examine compliance with these newer guidelines. 
Finally, while the identification of factors associ-
ated with decreased intravesical therapy use -- age, 
ethnicity, or type of practice -- gives clues as to the 
barriers preventing implementation, the main under-
lying issues may be failure to disseminate existing 
literature, patient burden (perceived or real), and lo-
gistical issues which affect provider work-flow.
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EDITORIAL COMMENT
 From a distance, it may look as if there is 
nothing new under the sun regarding management 
of non-muscle invasive transitional cell bladder can-
cer. We use urine cytology, transurethral resection, 
intravesical doxorubicin or mitomycin and BCG for 
more than 35 years and they remain our main weap-
ons for fighting not only costly (due to innumerous 
recurrences), but unpredictive and if progressive of-
ten fatal disease.
 At a closer look, the field of this disease has 
changed quite significantly in recent years. With-
out  considering new markers, drugs and techniques 
which are already available it may look promising in 
the future (studies evaluating screening with combi-
nations of new markers like FISH analysis of exfo-
liated cells in urine, proteomics, fluorescence blue 
light cystoscopy and resection, gentamycin, micro-
wave heated or electromotive intravesical drug ap-
plication). Main change has been in standardization 
and systematization of our approach to patients with 
this disease. Those changes took place in recent 
years and guidelines (AUA, NCCN and EAU) are 
all freely available from their respective web-sites. 
AUA guidelines are quite narrative and give reason-
ing behind suggestions, NCCN produces and every 
few months updates short and up to a point graphic 
algorithms - decision trees and EAU may has pro-
duced (in their last, 2009 update) most precise and 
straightforward set of rules for dealing with non-
muscle invasive bladder cancer.
 EAU rules seem to have almost taken “art” 
out of medicine in this area and “science” has al-
most completely taken over. Is this good? The pres-
ent article by Leliveld and coworkers shows us the 
importance of this aspect. Although titled “High 
risk bladder cancer: current management and sur-
vival”, they report only 35% of patients who were 
only treated some 8 years ago (in 2002), in a west-
ern European country, according to present regional 
(EAU) guidelines. This means 65% of high risk su-
perficial bladder cancers have not received immu-
notherapy (BCG), which they, according to present 
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guidelines, should have received. Although the au-
thors in discussion address this issue and cite one, 8 
year old study, which claims no survival advantage 
for immunotherapy group and this may be debatable, 
the fact still remains solid: majority of patients were 
at the time of study not treated according to pres-
ent guidelines. Some patients may be unsuitable (too 
old etc.) for treatment according to guidelines and 
guidelines have room for improvement with spe-
cifically addressing those marginal groups. Perhaps 
some patients may be in a registered clinical trial 
(this is not reported). But otherwise - current man-
agement of high risk bladder cancer should not be as 
was mentioned in this study. If not for other reasons, 
guidelines take a lot of hesitation out of our mind 
and help us a lot in ultimate question with high risk 
patients – i.e. to proceed with cystectomy or contin-
ue conservative treatment? Decision for cystectomy 
is a difficult one and it is universally accepted it is 
often made too late (1). Relatively rigid guidelines 
offer a highway towards this decision, if and when 
needed. Although guidelines can and will change 
with time, obeying them is a first step towards im-
proving outcomes, which for bladder cancer seem to 
remain the same for decades with no improvement. 
Only years after we have standardized our approach 
and try to follow guidelines with each individual pa-
tient, SEER and other cancer statistics may and will 
reflect improvements.
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